Singapore markets close in 5 hours 51 minutes

Ultragenyx Pharmaceutical Inc. (0LIF.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
41.88-2.34 (-5.29%)
At close: 07:03PM BST

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415 483 8800

Full-time employees1,276

Key executives

NameTitlePayExercisedYear born
Dr. Emil D. Kakkis M.D., Ph.D.Founder, President, CEO & Director1.37MN/A1960
Mr. John Richard Pinion IIChief Quality Operations Officer & Executive VP of Translational Sciences806.19kN/A1966
Mr. Erik HarrisExecutive VP & Chief Commercial Officer848.24kN/A1971
Mr. Howard HornExecutive VP of Corporate Strategy & CFON/AN/A1978
Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting OfficerN/AN/A1971
Ms. Danielle KeatleySenior Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Karah Herdman Parschauer J.D.Chief Legal Officer & Executive VP of Corporate Affairs595.01k122k1978
Mr. Ernie W. MeyerChief Human Resources Officer & Executive VPN/AN/A1965
Mr. Thomas R. KassbergChief Business Officer & Executive VP714.84kN/A1960
Mr. Vimal SrivastavaSenior Vice President of Business Development & Alliance ManagementN/AN/A1965
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Corporate governance

Ultragenyx Pharmaceutical Inc.’s ISS governance QualityScore as of 1 April 2024 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.